{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:07Z","timestamp":1785110407352,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":116,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Shapingba District Health Commission","award":["2023SQKWLH021"],"award-info":[{"award-number":["2023SQKWLH021"]}]},{"name":"Chongqing Health Commission","award":["2023MSXM043"],"award-info":[{"award-number":["2023MSXM043"]}]},{"name":"Chongqing Health Commission","award":["2023ZDXM029"],"award-info":[{"award-number":["2023ZDXM029"]}]},{"name":"Scientific and Technological Research Program of Chongqing Municipal Education Commission","award":["KJQN20230013"],"award-info":[{"award-number":["KJQN20230013"]}]},{"name":"Beijing Health Alliance Charitable Foundation","award":["BJHA-CRP-089"],"award-info":[{"award-number":["BJHA-CRP-089"]}]},{"name":"Talent Program of Chongqing","award":["YXGD202403"],"award-info":[{"award-number":["YXGD202403"]}]},{"name":"Talent Program of Chongqing","award":["cstc2024rcih-bgzxm0162"],"award-info":[{"award-number":["cstc2024rcih-bgzxm0162"]}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Bureau","doi-asserted-by":"crossref","award":["cstc2022jxjl20039"],"award-info":[{"award-number":["cstc2022jxjl20039"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Project for Enhancing Scientific Research Capabilities of Chongqing University Cancer Hospital","award":["2023nlts009"],"award-info":[{"award-number":["2023nlts009"]}]},{"DOI":"10.13039\/501100005230","name":"Chongqing\u00a0Natural Science Foundation","doi-asserted-by":"crossref","award":["2024NSCQ-MSX1295"],"award-info":[{"award-number":["2024NSCQ-MSX1295"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing medical scientific research project","award":["No.2024jstg043"],"award-info":[{"award-number":["No.2024jstg043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02086-x","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:06:40Z","timestamp":1775110000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CC223 enhances cisplatin sensitivity of platinum-resistant ovarian cancer by inducing cell cycle arrest"],"prefix":"10.1186","volume":"19","author":[{"given":"Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongling","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"2086_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2086_CR2","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"2086_CR3","doi-asserted-by":"crossref","unstructured":"Yang L et al. Molecular mechanisms of platinum\u2013based chemotherapy resistance in ovarian cancer (Review). Oncol Rep, 2022. 47(4) : 82 .","DOI":"10.3892\/or.2022.8293"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2086_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"45","key":"2086_CR6","doi-asserted-by":"publisher","first-page":"11818","DOI":"10.1073\/pnas.1716173114","volume":"114","author":"DM Sabatini","year":"2017","unstructured":"Sabatini DM. Twenty-five years of mTOR: Uncovering the link from nutrients to growth. Proc Natl Acad Sci U S A. 2017;114(45):11818\u201325.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2086_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13046-025-03482-9","volume":"44","author":"R Guan","year":"2025","unstructured":"Guan R, et al. MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K\/AKT\/mTOR signaling pathway. J Exp Clin Cancer Res. 2025;44(1):221.","journal-title":"J Exp Clin Cancer Res"},{"key":"2086_CR8","doi-asserted-by":"crossref","unstructured":"Mir SA et al. Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer. Pharmaceuticals (Basel), 2023. 16(7) :1004 .","DOI":"10.3390\/ph16071004"},{"issue":"12","key":"2086_CR9","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1080\/15548627.2023.2239633","volume":"19","author":"CY Lin","year":"2023","unstructured":"Lin CY, et al. Starvation-inactivated MTOR triggers cell migration via a ULK1-SH3PXD2A\/TKS5-MMP14 pathway in ovarian carcinoma. Autophagy. 2023;19(12):3151\u201368.","journal-title":"Autophagy"},{"issue":"6","key":"2086_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41419-021-03828-z","volume":"12","author":"R Luc\u00e0","year":"2021","unstructured":"Luc\u00e0 R, et al. Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties. Cell Death Dis. 2021;12(6):558.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2086_CR11","first-page":"573","volume":"4","author":"N Rinne","year":"2021","unstructured":"Rinne N, et al. Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist. 2021;4(3):573\u201395.","journal-title":"Cancer Drug Resist"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"issue":"7606","key":"2086_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature17963","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","unstructured":"Rodrik-Outmezguine VS, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534(7606):272\u20136.","journal-title":"Nature"},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31.","journal-title":"Cell Biosci"},{"issue":"1","key":"2086_CR15","doi-asserted-by":"publisher","first-page":"2237209","DOI":"10.1080\/14756366.2023.2237209","volume":"38","author":"X Huang","year":"2023","unstructured":"Huang X, et al. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK). J Enzyme Inhib Med Chem. 2023;38(1):2237209.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"2086_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","volume":"22","author":"ES Ali","year":"2022","unstructured":"Ali ES, et al. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022;22(1):284.","journal-title":"Cancer Cell Int"},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"102886","DOI":"10.1016\/j.critrevonc.2020.102886","volume":"147","author":"L Formisano","year":"2020","unstructured":"Formisano L, et al. Mechanisms of resistance to mTOR inhibitors. Crit Rev Oncol Hematol. 2020;147:102886.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2086_CR18","doi-asserted-by":"publisher","first-page":"112820","DOI":"10.1016\/j.ejmech.2020.112820","volume":"208","author":"Y Chen","year":"2020","unstructured":"Chen Y, Zhou X. Research progress of mTOR inhibitors. Eur J Med Chem. 2020;208:112820.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"2086_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","volume":"14","author":"DS Mortensen","year":"2015","unstructured":"Mortensen DS, et al. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015;14(6):1295\u2013305.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2086_CR20","doi-asserted-by":"publisher","first-page":"e0221994","DOI":"10.1371\/journal.pone.0221994","volume":"14","author":"E Wolin","year":"2019","unstructured":"Wolin E, et al. A phase 2 study of an oral mTORC1\/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE. 2019;14(9):e0221994.","journal-title":"PLoS ONE"},{"issue":"3","key":"2086_CR21","doi-asserted-by":"publisher","first-page":"e0173252","DOI":"10.1371\/journal.pone.0173252","volume":"12","author":"Z Xie","year":"2017","unstructured":"Xie Z, et al. CC-223 blocks mTORC1\/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. PLoS ONE. 2017;12(3):e0173252.","journal-title":"PLoS ONE"},{"issue":"19","key":"2086_CR22","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1002\/cncr.29422","volume":"121","author":"JC Bendell","year":"2015","unstructured":"Bendell JC, et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015;121(19):3481\u201390.","journal-title":"Cancer"},{"issue":"3","key":"2086_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","volume":"157","author":"H Chen","year":"2020","unstructured":"Chen H, et al. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecol Oncol. 2020;157(3):783\u201392.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2086_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349.","journal-title":"Nat Med"},{"issue":"W1","key":"2086_CR25","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2086_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/0008-5472.CAN-20-1488","volume":"81","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. Cancer Res. 2021;81(2):384\u201399.","journal-title":"Cancer Res"},{"issue":"W1","key":"2086_CR27","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"2086_CR28","doi-asserted-by":"crossref","unstructured":"Gao X, et al. 4-Hydroxyderricin Promotes Apoptosis and Cell Cycle Arrest through Regulating PI3K\/AKT\/mTOR Pathway in Hepatocellular Cells. Foods. 2021;10(9):2036 .","DOI":"10.3390\/foods10092036"},{"issue":"1","key":"2086_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s11658-024-00578-6","volume":"29","author":"XQ Li","year":"2024","unstructured":"Li XQ, et al. Targeted inhibition of the PI3K\/AKT\/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer. Cell Mol Biol Lett. 2024;29(1):58.","journal-title":"Cell Mol Biol Lett"},{"issue":"6","key":"2086_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dmz027","volume":"25","author":"N Spears","year":"2019","unstructured":"Spears N, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673\u201393.","journal-title":"Hum Reprod Update"},{"key":"2086_CR31","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.ctrv.2020.102021","volume":"86","author":"TT Huang","year":"2020","unstructured":"Huang TT, et al. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2086_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2021.07.008","volume":"163","author":"P van der Ploeg","year":"2021","unstructured":"van der Ploeg P, et al. The effectiveness of monotherapy with PI3K\/AKT\/mTOR pathway inhibitors in ovarian cancer: A meta-analysis. Gynecol Oncol. 2021;163(2):433\u201344.","journal-title":"Gynecol Oncol"},{"key":"2086_CR33","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.2147\/OTT.S186186","volume":"11","author":"T Wu","year":"2018","unstructured":"Wu T, et al. Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2\/M phase arrest of HCC via PI3K\/AKT\/mTOR\/ERK signaling pathway. Onco Targets Ther. 2018;11:8633\u201342.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"2086_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ctrv.2012.02.001","volume":"38","author":"I Diaz-Padilla","year":"2012","unstructured":"Diaz-Padilla I, et al. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev. 2012;38(6):767\u201375.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"2086_CR35","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1021\/acs.jmedchem.5b00626","volume":"58","author":"DS Mortensen","year":"2015","unstructured":"Mortensen DS, et al. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. J Med Chem. 2015;58(13):5323\u201333.","journal-title":"J Med Chem"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02086-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02086-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02086-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:53:12Z","timestamp":1785109992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02086-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02086-x","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was reviewed and approved by the Animal Ethics Committee of Chongqing University Cancer Hospital. The experiments were approved by the Ethics Committee of Chongqing University Cancer Hospital (CZLS2020274-A).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"247"}}